Wednesday, BluePhoenix Solutions (BPHX) closed the acquisition of the business of DSKnowledge Ltd. for $2.25 million in cash and the assumption of liabilities of approximately $0.7 million pursuant to the asset purchase agreement executed by BluePhoenix and DSKnowledge and its affiliates on November 11, 2009. The closing conditions for the purchase of the services affiliated businesses of DSKnowledge were not fulfilled, and BluePhoenix only completed the purchase of the DSKnowledge business which includes the product business.
DSKnowledge is a leading provider of Knowledge Management software for enterprises. The company modernizes and transforms legacy data, information and content elements in enterprises into one knowledge management repository.
For comments and feedback contact: editorial@rttnews.com
November 03, 2026 10:34 ET A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.